Sabah - US pharmaceutical company Eli Lilly has shortlisted Turkey for its future investments, according to the company’s Senior Vice-President Bart Peterson. Known for its diabetes and cancer treatment drugs, Lilly is reported to be in talks for a possible partnership with a Turkish company, Nevzat Ibrahim.
“Lilly considers Turkey to be a top priority investment location,” said Peterson during a visit to Turkey, underlining Turkey’s economic growth and large domestic market. “Turkey is a major market with an advanced healthcare system. The investment environment is developing rapidly as well,” he noted, declining to comment on possible partnership deals.
“Our investment focus is on having a wide range of products. We are in a fast growth period in Turkey and the government’s steps in the last few years have increased the quality and accessibility of healthcare services significantly,” he added.